GLPG (Galapagos NV) Long-Term Debt : $0.0 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Long-Term Debt?

Galapagos NV's Long-Term Debt for the quarter that ended in Dec. 2024 was $0.0 Mil.

Galapagos NV Long-Term Debt Historical Data

The historical data trend for Galapagos NV's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Long-Term Debt Chart

Galapagos NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Debt

Get a 7-Day Free Trial

Galapagos NV Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Galapagos NV (NAS:GLPG) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Galapagos NV Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:Netherlands GLPGa:UK 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.